Please login to the form below

Not currently logged in
Email:
Password:

Zealand adds two observers to board of directors

Martin Nicklasson and Catherine Moukheibir join the firm
Martin Nicklasson

Denmark-based pharma company Zealand Pharma has added Dr Martin Nicklasson and Catherine Moukheibir the company's board of directors in the role of observers.

The announcement comes just days after the pharma company revealed Britt Meelby Jensen as its new CEO.

Nicklasson has held various executive VP positions at AstraZeneca and was president and CEO of BioVitrum and Swedish Orphan Biovitrum. He is also chairman of the board of Basilea, Orexo and Farma Holding.

Catherine Moukheibir has held senior management positions in several European biotech companies after an initial career in strategy consulting and investment banking. She is currently a non-executive board member of Creabilis and Ablynx.

Daniel Ellens, chairman of the Zealand board of directors, said: “They provide important and broad-based experience from public life science companies and are important additions to the competences on the board as we prepare for the next steps in Zealand's growth strategy as a maturing biotech company.”

12th November 2014

From: Research, Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
HAVAS Just::

HAVAS Just:: is a different kind of healthcare communications agency. Our mission is to create campaigns that make people think....

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics